Announcement
HPTN at CROI 2025
HPTN at CROI 2025
HPTN researchers presented 11 abstracts (seven orals and four posters) at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) from March 9-12 in San Francisco, CA.
Estimated Benefits of Providing On-Demand PrEP Options for Women in Cape Town: A Modeling Study
Learn more about HPTN 067
Use of DNA Profiling to Resolve Discrepant HIV Tests in the Setting of Injectable Cabotegravir PrEP
Learn more about HPTN 083
High Incidence of Curable Sexually Transmitted Infections in HPTN 084: A Tertiary Analysis
Learn more about HPTN 084
T Cell Responses in Two Cohorts of Former AMP Participants on Analytical Treatment Interruption
Learn more about HVTN 805/HPTN 093/A5390 and HVTN 804/HPTN 095/A5393
Fixed Dosing Versus Body-Weight-Based Dosing of HIV-1 Prophylactic Monoclonal Antibodies in Adults
Yunda Huang
Learn more about HVTN 703/HPTN 081, HVTN 704/HPTN 085, HVTN 127/HPTN 087, HVTN 130/HPTN 089, HVTN 136/HPTN 092, HVTN 140/HPTN 101
No Increased Risk for Hypertension with CAB-LA Compared to TDF/FTC for PrEP: Results from HPTN 084
Learn more about HPTN 084
Efficacy of Bivalent Versus Monovalent COVID-19 Vaccines Among People With HIV, Ubuntu Trial 2022-2024
Learn more about CoVPN 3008
Response to HIV Treatment After Long-Acting Cabotegravir Preexposure Prophylaxis in HPTN 083
slides unavailable
Learn more about HPTN 083
Performance of HIV RNA Screening in the Context of Long-Acting Injectable Cabotegravir
Learn more about HPTN 084
Preliminary Efficacy for HPTN 094: 26-Week RCT of Integrated Strategies for People Who Inject Drugs
Learn more about HPTN 094
Estimation of Prevention-Effective CAB-LA Concentrations Among MSM/TGW in HPTN 083
slides unavailable
Learn more about HPTN 094